Loading…
USPSTF Transparency and Accountability Act of 2012
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
59pct
11d open
vs 6,662 other HR bills in the 112th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (10)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2012 · fourth_quarter · Health Issues
Support the speedy implementation of the National Alzheimer's Project Act (NAPA) by HHS, and support Leaders Engaged on Alzheimer's Disease (LEAD) recommendations as to how to proceed. Support repeal of Section 6001 of the PPACA and remove all restrictions on physician-owned hospitals. (Support H.R. 1159 and H.R. 1186) Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid. Support all legislative and regulatory action to modernize the FDA and to speed new cures and therapies to patients. Support the Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 (S. 1096, H.R. 2020) Support Leaders Engaged on Alzheimer's Disease (LEAD) FY 2012 funding proposals in the amount of for $35 billion for the National Institutes of Health (NIH), $1.4 billion for the National Institute on Aging (NIA), $100 million for the Cures Acceleration Network (CAN), $11.46 million for the Alzheimer's Disease Supportive Services Program (ADSSP), $192 million for the National Family Caregiver Support Program (NFCSP), $50 million for the Lifespan Respite Care Program (LRCP), and$2.744 billion for the Food and Drug Administration (FDA), as well as $2 million for the Missing Alzheimer's Disease Patient Alert Program and $750,000 to organize and host a high-level meeting to focus on the global Alzheimer's disease crisis. Oppose proposals that would reduce Medicare payments for providers of drugs and biologics under Medicare Part B. Support the proposed Prescription Drug User Fee Act Reauthorization Agreement (PDUFA-V) now under consideration by the Congress for reauthorization. Support an extension of the Therapeutic Discovery Project Tax Credit (I.R.C. 48D). Oppose the proposed merger between pharmacy benefit managers (PBM) Medco Health Solutions (Medco) and Express Scripts, Inc. (ESI), including comments to the Federal Trade Commission on the merger's obvious danger to older Americans. Support the development of clearly-defined, comprehensive, patient-centric Essential Health Benefits rules under the Affordable Care Act. Support the Counterfeit Drug Penalty Enhancement Act of 2011. Joined other patient advocate organizations to urge the National Government Services to reconsider its policy regarding blanket denials under the Current Procedural Terminology (CPT) health and behavioral assessment and intervention codes (96150-96155) which restrict those medically appropriate services to Medicare beneficiaries with Alzheimer's disease. Joined other patient advocate organizations January 2012 to urge HHS to ensure that ACA "Essential Health Benefits" guidelines provide comprehensive, quality and affordable health care. This was in response to the HHS December 16, 2011 bulletin on Essential Health Benefits because the HHS bulletin did not provide adequate patient protections as intended under the ACA. Joined other patient advocate groups to support the Spending Reductions through Innovations in Therapies (SPRINT) Act (H.R. 3891 and S. 2064) Support H.R.5998, the USPSTF Transparency and Accountability Act of 2012. Support the creation of the National Center for AdvancingTranslations Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative." Support the new Centers for Disease Control recommendations regarding the identification of chronic Hepatitis C infections. Urge all providers and payers to follow those same CDC recommendations. Oppose the substitution and use of unapproved and off-label drugs to treat age-related macular degeneration (AMD). Urge the Department of HHS to adopt the Advisory Council on Alzheimer's Research recommendations and ensure that the final National Alzheimer's Plan includes measures: Providing high-level, overall accountability for National Plan implementation. Recognizing and proposing a path forward to secure the public and private resources needed to achieve all of the goals. Forming robust public-private partnerships between government and industry to inform the research agenda, shorten the time and cost of developing therapies, and accelerate delivery of safe and effective treatments to individuals with Alzheimers. Fostering greater collaboration on research and other issues with international counterparts to achieve global coordination and progress toward a Global Alzheimers Action Plan. Expanding attention on early detection and diagnosis of Alzheimers disease. Ensuring access to the full array of long-term support services for special and emerging populations of people with Alzheimers disease, including younger people and those with developmental disabilities. Addressing caregivers physical and behavioral health. Expanding access to high quality, cost-effective and evidence based care and redoubling efforts to test and validate innovative care interventions. Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Support stiff restrictions on biosimilar "flexibility" (intentionally introducing differences to the molecule or the finished product) that adds high risk. Support distinctive labeling for safety, and install a strong track and trace system before the first biosimilar is allowed on the market. Support Congressional review and oversight to examine the National Alzheimer's Plan implementation progress. Support "unique naming" requirements for all biologic drugs, especially biosimilar drugs, as a matter of patient safety. Support full Medicare funding for dual energy x-ray absorptiometry (DXA) test reimbursement to fight osteoporosis. Support new extended funding (as under the expired Medicare Improvements for Patients and Providers Act or MIPPA) for Medicare low-income outreach and enrollment activities. Support the Medicare Part D prescription drug benefit program and the needed improvements to correct its limitations; including gaps in coverage, onerous cost-shifting created by specialty tiers, and restrictive utilization management tools. Robust formularies, coverage of the six protected drug classes, strong oversight, and transparency for consumers are also critical, as is a process for notice of non-coverage, and an appeals and exceptions process that is patient and provider friendly. Support all measures making Alzheimer's disease a continued top priority at the U.S. Food and Drug Administration (FDA).
Client expense: $42,249 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2012 · fourth_quarter · Health Issues
Opposition to the U.S. Preventative Services Task Force (USPSTF) recommendation regarding the prostate-specific antigen test. Promotion of greater transparency of USPSTF. Support for H.R. 5998, "USPSTF Transparency and Accountability Act of 2012."
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Medicare/Medicaid
See page three for specific Medicare/Medicaid issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Proposed Rule Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Trauma Appropriations
Client expense: $70,254 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE
2012 · second_quarter · Health Issues
See page five for specific HCR issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Proposed Rule Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Trauma Appropriations
Client expense: $70,254 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE
2012 · fourth_quarter · Medicare/Medicaid
See page three for specific Medicare/Medicaid issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H. R. 1700 The Medicare Patient Empowerment Act H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5937 Breast Cancer Patient Education Act of 2012 H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 H. R. 6043 - Behavioral Health Information Technology Act of 2012 H.R. 6352 - Resident Physician Shortage Reduction and Graduate Medical Education Accountability & Transparency Act H. R. 6598 - Electronic Health Records Improvement Act S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Issues Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program HAI prevention Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization (MMM Continued) Physician Fee Schedule and OPPS/ASC CY 2012 Proposed Rule Physician Quality Reporting System (PQRS) Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule Risk pool legislation RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Sequestration Surgical Consumer Assessment of Healthcare Providers and Systems (S-CAHPS) Trauma Appropriations Value-Based Update (VBU) Proposal
Client expense: $16,647 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE
2012 · fourth_quarter · Health Issues
See page six for specific Health Care Issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H. R. 1700 The Medicare Patient Empowerment Act H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5937 Breast Cancer Patient Education Act of 2012 H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 H. R. 6043 - Behavioral Health Information Technology Act of 2012 H.R. 6352 - Resident Physician Shortage Reduction and Graduate Medical Education Accountability & Transparency Act H. R. 6598 - Electronic Health Records Improvement Act S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Issues Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program HAI prevention Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization (HCR Continued) Physician Fee Schedule and OPPS/ASC CY 2012 Proposed Rule Physician Quality Reporting System (PQRS) Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule Risk pool legislation RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Sequestration Surgical Consumer Assessment of Healthcare Providers and Systems (S-CAHPS) Trauma Appropriations Value-Based Update (VBU) Proposal
2012 · fourth_quarter · Medicare/Medicaid
See page three for specific Medicare/Medicaid issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H. R. 1700 The Medicare Patient Empowerment Act H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5937 Breast Cancer Patient Education Act of 2012 H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 H. R. 6043 - Behavioral Health Information Technology Act of 2012 H.R. 6352 - Resident Physician Shortage Reduction and Graduate Medical Education Accountability & Transparency Act H. R. 6598 - Electronic Health Records Improvement Act S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Issues Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program HAI prevention Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization (MMM Continued) Physician Fee Schedule and OPPS/ASC CY 2012 Proposed Rule Physician Quality Reporting System (PQRS) Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule Risk pool legislation RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Sequestration Surgical Consumer Assessment of Healthcare Providers and Systems (S-CAHPS) Trauma Appropriations Value-Based Update (VBU) Proposal
2012 · fourth_quarter · Health Issues
See page six for specific Health Care Issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H. R. 1700 The Medicare Patient Empowerment Act H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5937 Breast Cancer Patient Education Act of 2012 H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 H. R. 6043 - Behavioral Health Information Technology Act of 2012 H.R. 6352 - Resident Physician Shortage Reduction and Graduate Medical Education Accountability & Transparency Act H. R. 6598 - Electronic Health Records Improvement Act S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Issues Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program HAI prevention Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization (HCR Continued) Physician Fee Schedule and OPPS/ASC CY 2012 Proposed Rule Physician Quality Reporting System (PQRS) Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule Risk pool legislation RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Sequestration Surgical Consumer Assessment of Healthcare Providers and Systems (S-CAHPS) Trauma Appropriations Value-Based Update (VBU) Proposal
2012 · fourth_quarter · Health Issues
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - Issues related to Physician Payment Sunshine provisions. - Issues related to the "Regulation & Reimbursement of Diagnostics", regarding all provisions. - Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 2960, "National Diabetes Clinical Care Commission Act", regarding all provisions. - HR 3026, "Safeguarding America's Pharmaceutical Act of 2011", regarding all provisions. - Prescription Drug User Fee Act, regarding all provisions - Personalized Medicine Incentives and Regulation. - Issues related to Alzheimer's research. - HR 2939, "Pharmaceutical Stewardship Act of 2011", regarding all provisions. - HR 3497, "MODERN Cures Act of 2011", regarding all provisions. - HR 3207, "Modernizing Laboratory Test Standards for Patients Act of 2011", regarding all provisions. - S 1700, "Medical Device Regulatory Improvement Act", regarding all provisions. - S 1865, "Patient Access to Medical Innovation Act", regarding all provisions. - S 1995, "Medical Device Patient Safety Act", regarding all provisions. - Issues related to vision care coverage under PPACA. - Medical Device User Fee Act Reauthorization. - HR 1483, "The Drug Safety Enhancement Act of 2011", regarding all provisions. - HR 3847, "Safety of Untested and New Devices Act of 2012", regarding all provisions. - HR 3975, "A bill to extend provisions of the Pediatric Medical Device Safety and Improvement Act of 2007", regarding all provisions. - S 2113, "A bill to empower the Food and Drug Administration to ensure a clear and effective pathway that will encourage innovative products to benefit patients and improve public health." regarding all provisions. - S 2193, "Ensuring Safe Medical Devices for Patients", regarding all provisions. - HR 5, "Protecting Access to Healthcare (PATH) Act", regarding all provisions. - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - HR 5937, "Breast Cancer Patient Education Act of 2012", regarding all provisions. - HR 5998, "USPSTF Transparency and Accountability Act of 2012", regarding all provisions. - S 3187, "Food and Drug Administration Safety and Innovation Act", regarding all provisions. - S 2516, "Food and Drug Administration Safety and Innovation Act", regarding all provisions. - HR 6584, Verifying Authority and Legality In Drug Compounding Act of 2012, regarding all provisions.
2012 · fourth_quarter · Medicare/Medicaid
- HR 905/ S 733, "To Amend Part B or Title XVIII of the Social Security Act to exclude customary prompt pay discounts from Manufacturers to Wholesalers from the average sales price for drugs & biologicals under Medicare", regarding all provisions. - HR 1041, "The Fairness in Medicare Bidding Act", regarding all provisions. - Issues related to Medicare reimbursement for Clinical Laboratory Services. - HR 1041, "Fairness in Medicare Bidding Act", regarding all provisions. - Medicare Part D Letter - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - S 668, "Health Care Bureaucrats Elimination Act", regarding all provisions. - Issues related to Physician-owned Companies that manufacture or distribute medical devices. - S 1468/ HR 2787, "Medicare Diabetes Self-Management Training Act of 2011", regarding all provisions. - PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services. - Issues related to implantable medical devices. - HR 5998, "USPSTF Transparency and Accountability Act of 2012", regarding all provisions.
Client expense: $880,000 · Firm income: Not reported
2012 · fourth_quarter · Health Issues
Lobby Congress regarding ongoing prescription drug shortage crisis and device reclassification - Food and Drug Administration Safety and Innovation Act (S. 3187) Lobby in support of House (HR 1676) and Senate action requesting the FDA examine the current classification of indoor tanning beds. Support the United States Preventive Services Task Force (USPSTF) Transparency and Accountability Act of 2012 (HR 5998) which recognizes the role of specialty physicians in providing expert guidance for developing and updating preventive health recommendations.
Client expense: $274,307 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Health Issues
Support the speedy implementation of the National Alzheimer's Project Act (NAPA) by HHS, and support Leaders Engaged on Alzheimer's Disease (LEAD) recommendations as to how to proceed. Support repeal of Section 6001 of the PPACA and remove all restrictions on physician-owned hospitals. (Support H.R. 1159 and H.R. 1186) Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid. Support all legislative and regulatory action to modernize the FDA and to speed new cures and therapies to patients. Support the Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 (S. 1096, H.R. 2020) Support Leaders Engaged on Alzheimer's Disease (LEAD) FY 2012 funding proposals in the amount of for $35 billion for the National Institutes of Health (NIH), $1.4 billion for the National Institute on Aging (NIA), $100 million for the Cures Acceleration Network (CAN), $11.46 million for the Alzheimer's Disease Supportive Services Program (ADSSP), $192 million for the National Family Caregiver Support Program (NFCSP), $50 million for the Lifespan Respite Care Program (LRCP), and$2.744 billion for the Food and Drug Administration (FDA), as well as $2 million for the Missing Alzheimer's Disease Patient Alert Program and $750,000 to organize and host a high-level meeting to focus on the global Alzheimer's disease crisis. Oppose proposals that would reduce Medicare payments for providers of drugs and biologics under Medicare Part B. Support the proposed Prescription Drug User Fee Act Reauthorization Agreement (PDUFA-V) now under consideration by the Congress for reauthorization. Support an extension of the Therapeutic Discovery Project Tax Credit (I.R.C. 48D). Oppose the proposed merger between pharmacy benefit managers (PBM) Medco Health Solutions (Medco) and Express Scripts, Inc. (ESI), including comments to the Federal Trade Commission on the merger's obvious danger to older Americans. Support the development of clearly-defined, comprehensive, patient-centric Essential Health Benefits rules under the Affordable Care Act. Support the Counterfeit Drug Penalty Enhancement Act of 2011. Joined other patient advocate organizations to urge the National Government Services to reconsider its policy regarding blanket denials under the Current Procedural Terminology (CPT) health and behavioral assessment and intervention codes (96150-96155) which restrict those medically appropriate services to Medicare beneficiaries with Alzheimer's disease. Joined other patient advocate organizations January 2012 to urge HHS to ensure that ACA "Essential Health Benefits" guidelines provide comprehensive, quality and affordable health care. This was in response to the HHS December 16, 2011 bulletin on Essential Health Benefits because the HHS bulletin did not provide adequate patient protections as intended under the ACA. Joined other patient advocate groups to support the Spending Reductions through Innovations in Therapies (SPRINT) Act (H.R. 3891 and S. 2064) Support H.R.5998, the USPSTF Transparency and Accountability Act of 2012. Support the creation of the National Center for AdvancingTranslations Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative." Support the new Centers for Disease Control recommendations regarding the identification of chronic Hepatitis C infections. Urge all providers and payers to follow those same CDC recommendations. Oppose the substitution and use of unapproved and off-label drugs to treat age-related macular degeneration (AMD). Urge the Department of HHS to adopt the Advisory Council on Alzheimer's Research recommendations and ensure that the final National Alzheimer's Plan includes measures: Providing high-level, overall accountability for National Plan implementation. Recognizing and proposing a path forward to secure the public and private resources needed to achieve all of the goals. Forming robust public-private partnerships between government and industry to inform the research agenda, shorten the time and cost of developing therapies, and accelerate delivery of safe and effective treatments to individuals with Alzheimers. Fostering greater collaboration on research and other issues with international counterparts to achieve global coordination and progress toward a Global Alzheimers Action Plan. Expanding attention on early detection and diagnosis of Alzheimers disease. Ensuring access to the full array of long-term support services for special and emerging populations of people with Alzheimers disease, including younger people and those with developmental disabilities. Addressing caregivers physical and behavioral health. Expanding access to high quality, cost-effective and evidence based care and redoubling efforts to test and validate innovative care interventions. Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Support stiff restrictions on biosimilar "flexibility" (intentionally introducing differences to the molecule or the finished product) that adds high risk. Support distinctive labeling for safety, and install a strong track and trace system before the first biosimilar is allowed on the market. Support Congressional review and oversight to examine the National Alzheimer's Plan implementation progress. Support "unique naming" requirements for all biologic drugs, especially biosimilar drugs, as a matter of patient safety. Support full Medicare funding for dual energy x-ray absorptiometry (DXA) test reimbursement to fight osteoporosis. Support new extended funding (as under the expired Medicare Improvements for Patients and Providers Act or MIPPA) for Medicare low-income outreach and enrollment activities. Support the Medicare Part D prescription drug benefit program and the needed improvements to correct its limitations; including gaps in coverage, onerous cost-shifting created by specialty tiers, and restrictive utilization management tools. Robust formularies, coverage of the six protected drug classes, strong oversight, and transparency for consumers are also critical, as is a process for notice of non-coverage, and an appeals and exceptions process that is patient and provider friendly. Support all measures making Alzheimer's disease a continued top priority at the U.S. Food and Drug Administration (FDA).
2012 · third_quarter · Health Issues
Support the speedy implementation of the National Alzheimer's Project Act (NAPA) by HHS, and support Leaders Engaged on Alzheimer's Disease (LEAD) recommendations as to how to proceed. Support repeal of Section 6001 of the PPACA and remove all restrictions on physician-owned hospitals. (Support H.R. 1159 and H.R. 1186) Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid. Support all legislative and regulatory action to modernize the FDA and to speed new cures and therapies to patients. Support the Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 (S. 1096, H.R. 2020) Support Leaders Engaged on Alzheimer's Disease (LEAD) FY 2012 funding proposals in the amount of for $35 billion for the National Institutes of Health (NIH), $1.4 billion for the National Institute on Aging (NIA), $100 million for the Cures Acceleration Network (CAN), $11.46 million for the Alzheimer's Disease Supportive Services Program (ADSSP), $192 million for the National Family Caregiver Support Program (NFCSP), $50 million for the Lifespan Respite Care Program (LRCP), and$2.744 billion for the Food and Drug Administration (FDA), as well as $2 million for the Missing Alzheimer's Disease Patient Alert Program and $750,000 to organize and host a high-level meeting to focus on the global Alzheimer's disease crisis. Oppose proposals that would reduce Medicare payments for providers of drugs and biologics under Medicare Part B. Support the proposed Prescription Drug User Fee Act Reauthorization Agreement (PDUFA-V) now under consideration by the Congress for reauthorization. Support an extension of the Therapeutic Discovery Project Tax Credit (I.R.C. 48D). Oppose the proposed merger between pharmacy benefit managers (PBM) Medco Health Solutions (Medco) and Express Scripts, Inc. (ESI), including comments to the Federal Trade Commission on the merger's obvious danger to older Americans. Support the development of clearly-defined, comprehensive, patient-centric Essential Health Benefits rules under the Affordable Care Act. Support the Counterfeit Drug Penalty Enhancement Act of 2011. Joined other patient advocate organizations to urge the National Government Services to reconsider its policy regarding blanket denials under the Current Procedural Terminology (CPT) health and behavioral assessment and intervention codes (96150-96155) which restrict those medically appropriate services to Medicare beneficiaries with Alzheimer's disease. Joined other patient advocate organizations January 2012 to urge HHS to ensure that ACA "Essential Health Benefits" guidelines provide comprehensive, quality and affordable health care. This was in response to the HHS December 16, 2011 bulletin on Essential Health Benefits because the HHS bulletin did not provide adequate patient protections as intended under the ACA. Joined other patient advocate groups to support the Spending Reductions through Innovations in Therapies (SPRINT) Act (H.R. 3891 and S. 2064) Support H.R.5998, the USPSTF Transparency and Accountability Act of 2012. Support the creation of the National Center for AdvancingTranslations Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative." Support the new Centers for Disease Control recommendations regarding the identification of chronic Hepatitis C infections. Urge all providers and payers to follow those same CDC recommendations. Oppose the substitution and use of unapproved and off-label drugs to treat age-related macular degeneration (AMD). Urge the Department of HHS to adopt the Advisory Council on Alzheimer's Research recommendations and ensure that the final National Alzheimer's Plan includes measures: Providing high-level, overall accountability for National Plan implementation. Recognizing and proposing a path forward to secure the public and private resources needed to achieve all of the goals. Forming robust public-private partnerships between government and industry to inform the research agenda, shorten the time and cost of developing therapies, and accelerate delivery of safe and effective treatments to individuals with Alzheimers. Fostering greater collaboration on research and other issues with international counterparts to achieve global coordination and progress toward a Global Alzheimers Action Plan. Expanding attention on early detection and diagnosis of Alzheimers disease. Ensuring access to the full array of long-term support services for special and emerging populations of people with Alzheimers disease, including younger people and those with developmental disabilities. Addressing caregivers physical and behavioral health. Expanding access to high quality, cost-effective and evidence based care and redoubling efforts to test and validate innovative care interventions. Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Support stiff restrictions on biosimilar "flexibility" (intentionally introducing differences to the molecule or the finished product) that adds high risk. Support distinctive labeling for safety, and install a strong track and trace system before the first biosimilar is allowed on the market. Support Congressional review and oversight to examine the National Alzheimer's Plan implementation progress.
2012 · third_quarter · Health Issues
Lobby Congress regarding ongoing prescription drug shortage crisis and device reclassification - Food and Drug Administration Safety and Innovation Act (S. 3187). Lobby in support of House (HR 1676) and Senate action requesting the FDA examine the current classification of indoor tanning beds. Support the United States Preventive Services Task Force (USPSTF) Transparency and Accountability Act of 2012 (HR 5998) which recognizes the role of specialty physicians in providing expert guidance for developing and updating preventive health recommendations.
Client expense: $223,150 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Medicare/Medicaid
- HR 905/ S 733, "To Amend Part B or Title XVIII of the Social Security Act to exclude customary prompt pay discounts from Manufacturers to Wholesalers from the average sales price for drugs & biologicals under Medicare", regarding all provisions. - HR 1041, "The Fairness in Medicare Bidding Act", regarding all provisions. - Issues related to Medicare reimbursement for Clinical Laboratory Services. - HR 1041, "Fairness in Medicare Bidding Act", regarding all provisions. - Medicare Part D Letter - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - S 668, "Health Care Bureaucrats Elimination Act", regarding all provisions. - Issues related to Physician-owned Companies that manufacture or distribute medical devices. - S 1468/ HR 2787, "Medicare Diabetes Self-Management Training Act of 2011", regarding all provisions. - PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services. - Issues related to implantable medical devices. - HR 5998, "USPSTF Transparency and Accountability Act of 2012", regarding all provisions.
Client expense: $1,420,000 · Firm income: Not reported
2012 · third_quarter · Health Issues
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - Issues related to Physician Payment Sunshine provisions. - Issues generating antibiotic incentives. - HR 1282, "Generating Antibiotics Incentives Now Act of 2011", regarding all provisions. - Issues related to the "Regulation & Reimbursement of Diagnostics", regarding all provisions. - Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 2960, "National Diabetes Clinical Care Commission Act", regarding all provisions. - HR 3026, "Safeguarding America's Pharmaceutical Act of 2011", regarding all provisions. - Prescription Drug User Fee Act, regarding all provisions - Personalized Medicine Incentives and Regulation. - Issues related to Alzheimer's research. - HR 2939, "Pharmaceutical Stewardship Act of 2011", regarding all provisions. - HR 3497, "MODERN Cures Act of 2011", regarding all provisions. - HR 3207, "Modernizing Laboratory Test Standards for Patients Act of 2011", regarding all provisions. - S 1700, "Medical Device Regulatory Improvement Act", regarding all provisions. - S 1865, "Patient Access to Medical Innovation Act", regarding all provisions. - S 1995, "Medical Device Patient Safety Act", regarding all provisions. - Issues related to vision care coverage under PPACA. - Medical Device User Fee Act Reauthorization. - HR 1483, "The Drug Safety Enhancement Act of 2011", regarding all provisions. - HR 3847, "Safety of Untested and New Devices Act of 2012", regarding all provisions. - HR 3975, "A bill to extend provisions of the Pediatric Medical Device Safety and Improvement Act of 2007", regarding all provisions. - S 2113, "A bill to empower the Food and Drug Administration to ensure a clear and effective pathway that will encourage innovative products to benefit patients and improve public health." regarding all provisions. - S 2193, "Ensuring Safe Medical Devices for Patients", regarding all provisions. - HR 5, "Protecting Access to Healthcare (PATH) Act", regarding all provisions. - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - HR 5937, "Breast Cancer Patient Education Act of 2012", regarding all provisions. - HR 5998, "USPSTF Transparency and Accountability Act of 2012", regarding all provisions. - S 3187, "Food and Drug Administration Safety and Innovation Act", regarding all provisions. - S 2516, "Food and Drug Administration Safety and Innovation Act", regarding all provisions.
2012 · third_quarter · Health Issues
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 S. 3187, FDA Safety and Innovation Act H.R. 5998, USPSTF Transparency and Accountability Act H.R. 6544, Manufacturing Innovation in America Act H.R. 6160, Stop Tampering of Prescription Pills Act H.R. 436, Health Care Cost Reduction Act regarding medical device excise tax repeal Issues relating to bioequivalence and related administrative procedures Issues relating to DEA quotas for controlled substances Oversight of DEA Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations
Client expense: $510,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
S. 3187, Food and Drug Administration Safety and Innovation Act, provisions relating to drug shortages, antibiotic incentives, and combating diversion H.R. 5998, USPSTF Transparency and Accountability Act of 2012, all provisions H.R. 2119, Ryan Creedon Act of 2011, all provisions H.R. 3497, MODDERN Cures Act of 2011, all provisions H.R. 3207, Modernizing Laboratory Test Standards for Patients Act of 2011, all provisions H.R. 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011, all provisions H.R. 2182, Generating Antibiotic Incentives Now Act of 2011, all provisions H.R. 2960, National Diabetes Clinical Care Commission Act, all provisions H.R. 4384, Patient Safety and Drug Labeling Improvement Act, all provisions Clinical Registries ACA Implementation Insurance Exchanges Prescription Drug Abuse Drug diversion/mandatory CME for DEA Registrants/violence prevention Drug shortages Flexible Spending Accounts (FSAs) Delivery and Payment Reform Personalized Medicine Health Information Technology HIPAA Administrative Simplifications Health Insurance Reform Medical Licensing Boards and Scope of Practice
Client expense: $3,680,000 · Firm income: Not reported
2012 · third_quarter · Health Issues
Opposition to the U.S. Preventative Services Task Force (USPSTF) recommendation regarding the prostate-specific antigen test. Promotion of greater transparency of USPSTF. Support for H.R. 5998, "USPSTF Transparency and Accountability Act of 2012."
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
Support the speedy implementation of the National Alzheimer's Project Act (NAPA) by HHS, and support Leaders Engaged on Alzheimer's Disease (LEAD) recommendations as to how to proceed. Support repeal of Section 6001 of the PPACA and remove all restrictions on physician-owned hospitals. (Support H.R. 1159 and H.R. 1186) Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid. Support all legislative and regulatory action to modernize the FDA and to speed new cures and therapies to patients. Support the Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 (S. 1096, H.R. 2020) Support Leaders Engaged on Alzheimer's Disease (LEAD) FY 2012 funding proposals in the amount of for $35 billion for the National Institutes of Health (NIH), $1.4 billion for the National Institute on Aging (NIA), $100 million for the Cures Acceleration Network (CAN), $11.46 million for the Alzheimer's Disease Supportive Services Program (ADSSP), $192 million for the National Family Caregiver Support Program (NFCSP), $50 million for the Lifespan Respite Care Program (LRCP), and$2.744 billion for the Food and Drug Administration (FDA), as well as $2 million for the Missing Alzheimer's Disease Patient Alert Program and $750,000 to organize and host a high-level meeting to focus on the global Alzheimer's disease crisis. Oppose proposals that would reduce Medicare payments for providers of drugs and biologics under Medicare Part B. Support the proposed Prescription Drug User Fee Act Reauthorization Agreement (PDUFA-V) now under consideration by the Congress for reauthorization. Support an extension of the Therapeutic Discovery Project Tax Credit (I.R.C. 48D). Oppose the proposed merger between pharmacy benefit managers (PBM) Medco Health Solutions (Medco) and Express Scripts, Inc. (ESI), including comments to the Federal Trade Commission on the merger's obvious danger to older Americans. Support the development of clearly-defined, comprehensive, patient-centric Essential Health Benefits rules under the Affordable Care Act. Support the Counterfeit Drug Penalty Enhancement Act of 2011. Joined other patient advocate organizations to urge the National Government Services to reconsider its policy regarding blanket denials under the Current Procedural Terminology (CPT) health and behavioral assessment and intervention codes (96150-96155) which restrict those medically appropriate services to Medicare beneficiaries with Alzheimer's disease. Joined other patient advocate organizations January 2012 to urge HHS to ensure that ACA "Essential Health Benefits" guidelines provide comprehensive, quality and affordable health care. This was in response to the HHS December 16, 2011 bulletin on Essential Health Benefits because the HHS bulletin did not provide adequate patient protections as intended under the ACA. Joined other patient advocate groups to support the Spending Reductions through Innovations in Therapies (SPRINT) Act (H.R. 3891 and S. 2064) Support H.R.5998, the USPSTF Transparency and Accountability Act of 2012. Support the creation of the National Center for AdvancingTranslations Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative." Support the new Centers for Disease Control recommendations regarding the identification of chronic Hepatitis C infections. Urge all providers and payers to follow those same CDC recommendations. Oppose the substitution and use of unapproved and off-label drugs to treat age-related macular degeneration (AMD). Urge the Department of HHS to adopt the Advisory Council on Alzheimer's Research recommendations and ensure that the final National Alzheimer's Plan includes measures: Providing high-level, overall accountability for National Plan implementation. Recognizing and proposing a path forward to secure the public and private resources needed to achieve all of the goals. Forming robust public-private partnerships between government and industry to inform the research agenda, shorten the time and cost of developing therapies, and accelerate delivery of safe and effective treatments to individuals with Alzheimers. Fostering greater collaboration on research and other issues with international counterparts to achieve global coordination and progress toward a Global Alzheimers Action Plan. Expanding attention on early detection and diagnosis of Alzheimers disease. Ensuring access to the full array of long-term support services for special and emerging populations of people with Alzheimers disease, including younger people and those with developmental disabilities. Addressing caregivers physical and behavioral health. Expanding access to high quality, cost-effective and evidence based care and redoubling efforts to test and validate innovative care interventions. Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Support stiff restrictions on biosimilar "flexibility" (intentionally introducing differences to the molecule or the finished product) that adds high risk. Support distinctive labeling for safety, and install a strong track and trace system before the first biosimilar is allowed on the market. Support Congressional review and oversight to examine the National Alzheimer's Plan implementation progress.
2012 · third_quarter · Medicare/Medicaid
See page three for specific Medicare/Medicaid issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H. R. 1700 The Medicare Patient Empowerment Act H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5937 Breast Cancer Patient Education Act of 2012 H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Issues Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program HAI prevention Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization Physician Fee Schedule and OPPS/ASC CY 2012 Proposed Rule Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule Risk pool legislation RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Sequestration Trauma Appropriations Value-Based Update (VBU) Proposal
2012 · third_quarter · Health Issues
See page six for specific Health Issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H. R. 1700 The Medicare Patient Empowerment Act H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5937 Breast Cancer Patient Education Act of 2012 H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Issues Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program HAI prevention Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization Physician Fee Schedule and OPPS/ASC CY 2012 Proposed Rule Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule Risk pool legislation RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Sequestration Trauma Appropriations Value-Based Update (VBU) Proposal
2012 · third_quarter · Medicare/Medicaid
See page three for specific Medicare/Medicaid issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H. R. 1700 The Medicare Patient Empowerment Act H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5937 Breast Cancer Patient Education Act of 2012 H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Issues Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program HAI prevention Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization Physician Fee Schedule and OPPS/ASC CY 2012 Proposed Rule Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule Risk pool legislation RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Sequestration Trauma Appropriations Value-Based Update (VBU) Proposal
2012 · third_quarter · Health Issues
See page six for specific Health Issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H. R. 1700 The Medicare Patient Empowerment Act H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5937 Breast Cancer Patient Education Act of 2012 H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Issues Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program HAI prevention Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization Physician Fee Schedule and OPPS/ASC CY 2012 Proposed Rule Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule Risk pool legislation RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Sequestration Trauma Appropriations Value-Based Update (VBU) Proposal
2012 · third_quarter · Retirement
HR 5998, HR 1086, Prostate Cancer, IPAB, ACA, cancer issues, senior issues, men's health
Client expense: Not reported · Firm income: Not reported
2012 · third_quarter · Medical/Disease Research/Clinical Labs
HR 5998, HR 1086, Prostate Cancer, IPAB, ACA, cancer issues, senior issues, men's health
Client expense: Not reported · Firm income: Not reported
2012 · third_quarter · Health Issues
HR 5998, HR 1086, Prostate Cancer, IPAB, ACA, cancer issues, senior issues, men's health
Client expense: Not reported · Firm income: Not reported
2012 · third_quarter · Veterans
HR 5998, HR 1086, Prostate Cancer, IPAB, ACA, cancer issues, senior issues, men's health
Client expense: Not reported · Firm income: Not reported
2012 · third_quarter · Pharmacy
HR 5998, HR 1086, Prostate Cancer, IPAB, ACA, cancer issues, senior issues, men's health
Client expense: Not reported · Firm income: Not reported
2012 · third_quarter · Government Issues
HR 5998, HR 1086, Prostate Cancer, IPAB, ACA, cancer issues, senior issues, men's health
Client expense: Not reported · Firm income: Not reported
2012 · third_quarter · Medicare/Medicaid
HR 5998, HR 1086, Prostate Cancer, IPAB, ACA, cancer issues, senior issues, men's health
Client expense: Not reported · Firm income: Not reported
2012 · third_quarter · Science/Technology
HR 5998, HR 1086, Prostate Cancer, IPAB, ACA, cancer issues, senior issues, men's health
Client expense: Not reported · Firm income: Not reported
2012 · second_quarter · Health Issues
Opposition to the U.S. Preventative Services Task Force (USPSTF) recommendation regarding the prostate-specific antigen test. Promotion of greater transparency of USPSTF. Support for H.R. 5998, "USPSTF Transparency and Accountability Act of 2012."
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Health Issues
See page 6 for specific HCR issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Proposed Rule Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Trauma Appropriations
2012 · second_quarter · Medicare/Medicaid
See page three for specific MMM issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Proposed Rule Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Trauma Appropriations
2012 · second_quarter · Health Issues
See page six for specific HCR issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Proposed Rule Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Trauma Appropriations
2012 · second_quarter · Medicare/Medicaid
See page three for specific Medicare/Medicaid issues. H.R. 1409 - Quality Health Care Coalition Act of 2011 H.R. 157 - Health Care Safety Net Enhancement Act of 2011 H.R. 2104 - Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 H.R. 2119 - Ryan Creedon Act of 2011 H.R. 2405 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 H.R. 2600 - National Pediatric Acquired Brain Injury Plan Act of 2011 H.R. 3239 - Safeguarding Access For Every Medicare Patient Act H.R. 3474 - PRIME Act of 2011 H.R. 3586 - Good Samaritan Health Professionals Act of 2011 H.R. 4310 - National Defense Authorization Act for Fiscal Year 2013 H.R. 451 - Healthcare Truth and Transparency Act of 2011 H.R. 452 - Medicare Decisions Accountability Act of 2011 H.R. 5 - Protecting Access to Healthcare Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 5707 - Medicare Physician Payment Innovation Act of 2012 H.R. 5888 - Physician Reentry Demonstration Program Act H.R. 5998 - USPSTF Transparency and Accountability Act of 2012 S. 1099 - Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3201 - Graduate Medical Education Reform Act of 2012 Accountable Care Organizations Final Rule ACS VBU (Value Based-Update) proposal Ambulatory Surgical Centers Cancer programs appropriations Children's Hospitals Graduate Medical Education Payment Program funding CMS EHR Stage 2 Proposed Rule CMS RUC Refinement Electronic Health Record Meaningful Use Stage 2 Proposed Rule Federal Privacy laws Health Information Technology (45 CFR Part 170) HHS ASPR/MSET Program Imaging Inspiring Quality Campaign IPAB Medical Device User Fee and Modernization Act (MDUFMA) Medicare audit programs Medicare fraud identification efforts Medicare Inpatient Prospective Payment System Proposed Rule Medicare Liability Reform Medicare SGR and Overseas Contingency Operations funds NIH Appropriations Nominations for the Committee on Governance and Financing of Graduate Medical Education Nominations for the Medicare Payment Advisory Commission Pediatric subspecialty loan repayment program Prescription Drug User Fee Act (PDUFA) reauthorization Quality and Value Based Purchasing Provisions of Medicare Physician Fee Schedule Final Rule RUC Refinement panel valuation problem Rx Drug and Surgical Workforce shortages Trauma Appropriations
2012 · second_quarter · Health Issues
Support the speedy implementation of the National Alzheimer's Project Act (NAPA) by HHS, and support Leaders Engaged on Alzheimer's Disease (LEAD) recommendations as to how to proceed. Support repeal of Section 6001 of the PPACA and remove all restrictions on physician-owned hospitals. (Support H.R. 1159 and H.R. 1186) Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid. Support all legislative and regulatory action to modernize the FDA and to speed new cures and therapies to patients. Support the Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 (S. 1096, H.R. 2020) Support Leaders Engaged on Alzheimer's Disease (LEAD) FY 2012 funding proposals in the amount of for $35 billion for the National Institutes of Health (NIH), $1.4 billion for the National Institute on Aging (NIA), $100 million for the Cures Acceleration Network (CAN), $11.46 million for the Alzheimer's Disease Supportive Services Program (ADSSP), $192 million for the National Family Caregiver Support Program (NFCSP), $50 million for the Lifespan Respite Care Program (LRCP), and$2.744 billion for the Food and Drug Administration (FDA), as well as $2 million for the Missing Alzheimer's Disease Patient Alert Program and $750,000 to organize and host a high-level meeting to focus on the global Alzheimer's disease crisis. Oppose proposals that would reduce Medicare payments for providers of drugs and biologics under Medicare Part B. Support the proposed Prescription Drug User Fee Act Reauthorization Agreement (PDUFA-V) now under consideration by the Congress for reauthorization. Support an extension of the Therapeutic Discovery Project Tax Credit (I.R.C. 48D). Oppose the proposed merger between pharmacy benefit managers (PBM) Medco Health Solutions (Medco) and Express Scripts, Inc. (ESI), including comments to the Federal Trade Commission on the merger's obvious danger to older Americans. Support the development of clearly-defined, comprehensive, patient-centric Essential Health Benefits rules under the Affordable Care Act. Support the Counterfeit Drug Penalty Enhancement Act of 2011. Joined other patient advocate organizations to urge the National Government Services to reconsider its policy regarding blanket denials under the Current Procedural Terminology (CPT) health and behavioral assessment and intervention codes (96150-96155) which restrict those medically appropriate services to Medicare beneficiaries with Alzheimer's disease. Joined other patient advocate organizations January 2012 to urge HHS to ensure that ACA "Essential Health Benefits" guidelines provide comprehensive, quality and affordable health care. This was in response to the HHS December 16, 2011 bulletin on Essential Health Benefits because the HHS bulletin did not provide adequate patient protections as intended under the ACA. Joined other patient advocate groups to support the Spending Reductions through Innovations in Therapies (SPRINT) Act (H.R. 3891 and S. 2064) Support H.R.5998, the USPSTF Transparency and Accountability Act of 2012. Support the creation of the National Center for AdvancingTranslations Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative." Support the new Centers for Disease Control recommendations regarding the identification of chronic Hepatitis C infections. Urge all providers and payers to follow those same CDC recommendations. Oppose the substitution and use of unapproved and off-label drugs to treat age-related macular degeneration (AMD). Urge the Department of HHS to adopt the Advisory Council on Alzheimer's Research recommendations and ensure that the final National Alzheimer's Plan includes measures: Providing high-level, overall accountability for National Plan implementation. Recognizing and proposing a path forward to secure the public and private resources needed to achieve all of the goals. Forming robust public-private partnerships between government and industry to inform the research agenda, shorten the time and cost of developing therapies, and accelerate delivery of safe and effective treatments to individuals with Alzheimers. Fostering greater collaboration on research and other issues with international counterparts to achieve global coordination and progress toward a Global Alzheimers Action Plan. Expanding attention on early detection and diagnosis of Alzheimers disease. Ensuring access to the full array of long-term support services for special and emerging populations of people with Alzheimers disease, including younger people and those with developmental disabilities. Addressing caregivers physical and behavioral health. Expanding access to high quality, cost-effective and evidence based care and redoubling efforts to test and validate innovative care interventions. Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Support stiff restrictions on biosimilar "flexibility" (intentionally introducing differences to the molecule or the finished product) that adds high risk. Support distinctive labeling for safety, and install a strong track and trace system before the first biosimilar is allowed on the market.
2012 · second_quarter · Health Issues
Support the speedy implementation of the National Alzheimer's Project Act (NAPA) by HHS, and support Leaders Engaged on Alzheimer's Disease (LEAD) recommendations as to how to proceed. Support repeal of Section 6001 of the PPACA and remove all restrictions on physician-owned hospitals. (Support H.R. 1159 and H.R. 1186) Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid. Support all legislative and regulatory action to modernize the FDA and to speed new cures and therapies to patients. Support the Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 (S. 1096, H.R. 2020) Support Leaders Engaged on Alzheimer's Disease (LEAD) FY 2012 funding proposals in the amount of for $35 billion for the National Institutes of Health (NIH), $1.4 billion for the National Institute on Aging (NIA), $100 million for the Cures Acceleration Network (CAN), $11.46 million for the Alzheimer's Disease Supportive Services Program (ADSSP), $192 million for the National Family Caregiver Support Program (NFCSP), $50 million for the Lifespan Respite Care Program (LRCP), and$2.744 billion for the Food and Drug Administration (FDA), as well as $2 million for the Missing Alzheimer's Disease Patient Alert Program and $750,000 to organize and host a high-level meeting to focus on the global Alzheimer's disease crisis. Oppose proposals that would reduce Medicare payments for providers of drugs and biologics under Medicare Part B. Support the proposed Prescription Drug User Fee Act Reauthorization Agreement (PDUFA-V) now under consideration by the Congress for reauthorization. Support an extension of the Therapeutic Discovery Project Tax Credit (I.R.C. 48D). Oppose the proposed merger between pharmacy benefit managers (PBM) Medco Health Solutions (Medco) and Express Scripts, Inc. (ESI), including comments to the Federal Trade Commission on the merger's obvious danger to older Americans. Support the development of clearly-defined, comprehensive, patient-centric Essential Health Benefits rules under the Affordable Care Act. Support the Counterfeit Drug Penalty Enhancement Act of 2011. Joined other patient advocate organizations to urge the National Government Services to reconsider its policy regarding blanket denials under the Current Procedural Terminology (CPT) health and behavioral assessment and intervention codes (96150-96155) which restrict those medically appropriate services to Medicare beneficiaries with Alzheimer's disease. Joined other patient advocate organizations January 2012 to urge HHS to ensure that ACA "Essential Health Benefits" guidelines provide comprehensive, quality and affordable health care. This was in response to the HHS December 16, 2011 bulletin on Essential Health Benefits because the HHS bulletin did not provide adequate patient protections as intended under the ACA. Joined other patient advocate groups to support the Spending Reductions through Innovations in Therapies (SPRINT) Act (H.R. 3891 and S. 2064) Support H.R.5998, the USPSTF Transparency and Accountability Act of 2012. Support the creation of the National Center for AdvancingTranslations Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative." Support the new Centers for Disease Control recommendations regarding the identification of chronic Hepatitis C infections. Urge all providers and payers to follow those same CDC recommendations. Oppose the substitution and use of unapproved and off-label drugs to treat age-related macular degeneration (AMD). Urge the Department of HHS to adopt the Advisory Council on Alzheimer's Research recommendations and ensure that the final National Alzheimer's Plan includes measures: Providing high-level, overall accountability for National Plan implementation. Recognizing and proposing a path forward to secure the public and private resources needed to achieve all of the goals. Forming robust public-private partnerships between government and industry to inform the research agenda, shorten the time and cost of developing therapies, and accelerate delivery of safe and effective treatments to individuals with Alzheimers. Fostering greater collaboration on research and other issues with international counterparts to achieve global coordination and progress toward a Global Alzheimers Action Plan. Expanding attention on early detection and diagnosis of Alzheimers disease. Ensuring access to the full array of long-term support services for special and emerging populations of people with Alzheimers disease, including younger people and those with developmental disabilities. Addressing caregivers physical and behavioral health. Expanding access to high quality, cost-effective and evidence based care and redoubling efforts to test and validate innovative care interventions. Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Support stiff restrictions on biosimilar "flexibility" (intentionally introducing differences to the molecule or the finished product) that adds high risk. Support distinctive labeling for safety, and install a strong track and trace system before the first biosimilar is allowed on the market.
| Democratic |
| VI |
| Jo Bonner | Republican | AL |
| Joe Baca | Democratic | CA |
| Joe Wilson | Republican | SC |
| John Barrow | Democratic | GA |
| Larry Kissell | Democratic | NC |
| Lee Terry | Republican | NE |
| Robert J. Wittman | Republican | VA |
| Rodney P. Frelinghuysen | Republican | NJ |
| Tim Walberg | Republican | MI |
| Tom Price | Republican | GA |
Client expense: $16,647 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE
Client expense: $87,126 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE
Client expense: $87,126 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE
Client expense: $880,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Client expense: Not reported · Firm income: $6,710
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $75,187 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Client expense: $1,420,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
Client expense: Not reported · Firm income: $9,625
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $15,870 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
Client expense: $15,870 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
Client expense: $75,279 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
Client expense: $75,279 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
Client expense: $8,713 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
Client expense: $8,713 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
Client expense: $70,254 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
Client expense: $70,254 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
Client expense: Not reported · Firm income: $10,808
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $61,150 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE